Targeting the intracellular WT1 oncogene product with a therapeutic human antibody.

@article{Dao2013TargetingTI,
  title={Targeting the intracellular WT1 oncogene product with a therapeutic human antibody.},
  author={Tao Dao and Su Yan and Nicholas J Veomett and Dmitry Pankov and Liang Zhou and Tatyana Korontsvit and Andrew Scott and Joseph A. Whitten and Peter G. Maslak and Emily Casey and Taochao Tan and Hong Liu and Victoria Zakhaleva and Michael Curcio and Ekaterina S. Doubrovina and Richard J O'reilly and Cheng Liu and David A. Scheinberg},
  journal={Science translational medicine},
  year={2013},
  volume={5 176},
  pages={176ra33}
}
The Wilms tumor 1 (WT1) oncoprotein is an intracellular, oncogenic transcription factor that is overexpressed in a wide range of leukemias and solid cancers. RMFPNAPYL (RMF), a WT1-derived CD8+ T cell human leukocyte antigen (HLA)-A0201 epitope, is a validated target for T cell-based immunotherapy. Using phage display technology, we discovered a fully human "T cell receptor-like" monoclonal antibody (mAb), ESK1, specific for the WT1 RMF peptide/HLA-A0201 complex. ESK1 bound to several leukemia… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 17 times over the past 90 days. VIEW TWEETS
48 Citations
0 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 48 extracted citations

Similar Papers

Loading similar papers…